Neuronetics Inc
NASDAQ:STIM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Neuronetics Inc
NASDAQ:STIM
|
89.7m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.9B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.7B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Neuronetics Inc is 50.4%, which is below its 3-year median of 69.8%.
Over the last 3 years, Neuronetics Inc’s Gross Margin has decreased from 76.4% to 50.4%. During this period, it reached a low of 50.4% on Sep 30, 2025 and a high of 76.4% on Sep 30, 2022.
